Coherus BioSciences Inc (CHRS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Coherus BioSciences Inc (CHRS) has a cash flow conversion efficiency ratio of -0.323x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.72 Million) by net assets ($61.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CHRS days of operational coverage to measure how many days the company can operate on defensive assets alone.
Coherus BioSciences Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Coherus BioSciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Coherus BioSciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Coherus BioSciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Topco Technologies
TWO:3388
|
0.039x |
|
Starpharma Holdings Ltd
AU:SPL
|
0.182x |
|
RAINBOW RARE EARTHS LTD
F:RR1
|
N/A |
|
Willy Food
TA:WLFD
|
0.028x |
|
Meridian Bank
NASDAQ:MRBK
|
-0.030x |
|
Wendell Industrial Co. Ltd
TWO:6761
|
0.048x |
|
Gaon Group Ltd
TA:GAGR
|
0.123x |
|
Stoneridge Inc
NYSE:SRI
|
0.056x |
Annual Cash Flow Conversion Efficiency for Coherus BioSciences Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Coherus BioSciences Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Coherus BioSciences Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $61.01 Million | $-138.51 Million | -2.270x | -1565.96% |
| 2024-12-31 | $-131.99 Million | $-20.44 Million | 0.155x | -82.87% |
| 2023-12-31 | $-193.43 Million | $-174.88 Million | 0.904x | -48.47% |
| 2022-12-31 | $-137.42 Million | $-241.12 Million | 1.755x | +558.10% |
| 2021-12-31 | $97.73 Million | $-37.43 Million | -0.383x | -169.82% |
| 2020-12-31 | $280.97 Million | $154.15 Million | 0.549x | +103.57% |
| 2019-12-31 | $105.21 Million | $28.36 Million | 0.269x | -93.47% |
| 2018-12-31 | $-38.59 Million | $-159.27 Million | 4.127x | +162.92% |
| 2017-12-31 | $30.54 Million | $-200.29 Million | -6.559x | +49.73% |
| 2016-12-31 | $19.35 Million | $-252.54 Million | -13.049x | -183.72% |
| 2015-12-31 | $-6.93 Million | $-107.99 Million | 15.585x | +4448.32% |
| 2014-12-31 | $66.76 Million | $-23.93 Million | -0.358x | +1.51% |
| 2013-12-31 | $-42.38 Million | $15.42 Million | -0.364x | +81.67% |
| 2012-12-31 | $9.19 Million | $-18.25 Million | -1.986x | -- |
About Coherus BioSciences Inc
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin… Read more